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loss). Depending on perspective chosen (e.g., 
citizen, third party payer or society) most tri-
als face difficulties to encompass all disease-
related costs. In the attempt to resolve these 
methodological issues, cost analysis along-
side clinical trials on efficiency have become 
the most widely exploited study design pro-
viding detailed picture on individual patient’s 
services consumption and expenditure. This 
review aims at providing comprehensive 
comparison of up-to-date knowledge on 
community-acquired pneumonia economic 
consequences worldwide.
COMMUNITY-ACQUIRED 
PNEUMONIA
Community-acquired pneumonia (CAP) is 
defined as potentially severe disease with 
high incidence and significant economic 
COST OF ILLNESS: 
ANALYSIS APPROACH
The awareness about health service resources 
limitation is increasing in medical circles 
throughout the world, and the number of 
studies dedicated to the use of these resourc-
es, often related to particular diseases, is 
increasing during recent years. Past few de-
cades of dynamic development of health eco-
nomics worldwide have brought new meth-
odological approaches to medical care costs 
assesment. Cost-of-illness analysis is based 
on descriptive assessment of “real world”cost 
matrix associated with particular health con-
ditions. These trials can be planned either as 
prospective or retrospective. Essentially, they 
mostly provide an in-depth follow up of pa-
tients suffering from certain disorder. Thus 
we get insight into both direct medical costs 
of care and indirect ones (e.g., productivity 
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ABSTRACT
Community-acquired pneumonia (CAP) represents a potentially severe illness with high incidence and significant econom-
ic impact. The estimated incidence varies from 1.6 to 13.4 cases/1000 inhabitants per year. Its burden of disease is attributed 
to high morbidity, mortality and serious health care utilization and expenditure throughout the world. The identification 
of determinants of high treatment costs could help in defining strategies for their reduction and more efficient use of the 
existing resources. In this article, a review of the existing literature about CAP cost-of-illness is provided, together with 
some considerations about possible strategies to decrease CAP costs in the Serbian health care setting. Available reports 
from cost-of-illness trials of CAP are relatively scarce. Most of them highlight the high costs generated by treatment pro-
tocols, with important differences between inpatients and outpatients. The inpatient cases of CAP varies from 18 to 60%. 
The therapy represents 10 to 15% of the overall costs of CAP. The costs of CAP treatment among inpatients are 7.9 times 
higher than those in outpatients. In case of complications and prolonged length of stay, this difference could even be 17 to 
51 times higher. Frequent hospital admissions could be avoided, which would reduce the costs of CAP treatment. An im-
portant precondition for successful cost containment would be higher adherence to clinical guidelines, particularly reflected 
through Pneumonia Severity Index-a (PSI) application. Thus, it would be possible to significantly reduce the length of stay 
in hospital, in majority of patients, without jeopardizing their health or influencing the clinical course of illness.
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impact. It is commonly defined as an acute 
infection of the lung parenchyma that is asso-
ciated with at least some symptoms of acute 
infection, accompanied by the presence of 
an acute infiltrate on a chest radiograph or 
auscultatory findings consistent with pneu-
monia (such as altered breathing sounds and/
or localized rales), in a patient not hospital-
ized or residing in a long-term-care facility 
for >14 days before onset of symptoms. The 
most common causative agents for CAP in-
clude Streptococcus pneumoniae, Mycoplas-
ma pneumoniae, Chlamydia pneumoniae, 
Haemophilus influenzae, viruses and other 
agents. Widespread misuse of antibiotics 
leads to an emerging antimicrobial resis-
tance, especially to penicillines, but also to 
macrolides and quinolones [1]. The estimat-
ed incidence of this disease varies from 1.6 to 
13.4 cases per 1000 inhabitants per year. In 
the United States, pneumonia is considered 
to be the sixth most common cause of death. 
In the period from 1979 to 1994, the overall 
rates of death due to pneumonia and influ-
enza increased by 59% (on the basis of ICD-
9 classification of mortality data from death 
certificates) in the United States [2]. Much of 
this increase is due to a greater proportion of 
persons aged >65 years; however, age-adjust-
ed rates also increased by 22%, which sug-
gests that other factors may have contributed 
to a changing epidemiology of pneumonia, 
including a greater proportion of the popu-
lation with underlying medical conditions at 
increased risk of respiratory infection [3].
In Europe, the incidence of CAP is known 
only in small areas of three countries (Spain, 
UK, and Finland) and in a more represen-
tative sample of the entire country in Italy. 
However, from the available data, it is no-
ticeable that a gradient of incidence from 
north to south is present in Europe, from 11 
per 1000 in Finland [4] down to 1.6 per 1000 
in Spain [5] and Italy [6]. It is interesting to 
note that in Italy the same north-south gra-
dient is present among the different areas of 
the same country. Moreover, the incidence 
of pneumonia increases with age with very 
consistent data in all countries. Estimations 
of the incidence, based on the reported data 
in the community, suggest a frequency of 
1-5/1000 inhabitants per year, althought there 
are considerable variations in the estimation 
of incidence of this disease [6]. Identification 
of the true CAP incidence is difficult because 
the condition is not easy to define without ac-
cess to a chest radiograph. Therefore, many 
patients are being dignosed and treated with-
out radiographic confirmation. Very common 
mistakes happen, when other pulmonary dis-
eases are being considered as CAP, unless the 
disease is being followed to its final outcome. 
CAP encompasses a range of illness sever-
ity from very mild to life-threatening. Most 
cases are mild and managed in the commu-
nity where chest radiographs may not be eas-
ily available. This disease is more frequent 
in the under 5 years of age group and least 
common in persons aged 15-29 [7]. From the 
mid forties, the frequency rises again until it 
becomes very common in the elderly. 
Precise figures on the health care and eco-
nomic burden are hard to collect. This hap-
pens because these data are related to the 
incidence of the condition, which is incom-
pletely known, and the way in which the con-
dition interfaces with the health care system, 
which differs from country to country.
Prospective studies suggest that mortality 
rates vary from 1-5% for patients managed 
at home, up to 15.8% for patients admitted 
to hospital and even up to 50% for patients 
admitted to the Intensive Care Unit (ICU) 
[5,8-13].
The burden of disease for CAP is being attrib-
uted to high morbidity, mortality and serious 
health care services utilization and expendi-
ture throughout the world. Community-ac-
quired pneumonia appears more frequently 
in elderly patients with comorbidities, which 
in the circumstances of progressively ageing 
population, leads to longer average length of 
stay in hospital and increased costs of treat-
ment and medical care. Ageing population 
and increased life expectancy in patients 
with chronical diseases and emerging antimi-
crobial resistance lead to complicated cases 
of community-acquired pneumonia, which 
means that in the future the burden and costs 
of CAP are going to increase.
The main direct costs of illness are gener-
ated through patient’s hospitalization, and 
they may be even up to 90% of overall costs 
related to CAP. The costs of stay in hospital, 
antibiotic and oxygen therapy are the most 
important components of direct costs. These 
components are influenced greatly by the 
initial severity of the disease and the course 
of illness during hospitalization. Comorbidi-
ties and complications during treatment have 
great impact on the overall cost of illness. 
Indirect costs of CAP comprise the lost of 
working days or patient’s inability to conduct 
regular activities, and since CAP is a poten-
tially fatal disease, potential lost of life years. 
Intangible costs could also be taken into ac-
count, even though they are cosidered less im-
portant, since CAP is an acute illness. They 
comprise the loss of self care capability, which 
is especially notable in older population.
The identification of determinants of high 
treatment costs could help in defining strat-
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egies of their reduction and more efficient 
utilisation of the existing resources.
SELECTION OF PUBLISHED 
EVIDENCE ON CAP COSTS
The available reports on pharmacoeconomic 
surveys of CAP prevention, diagnosis and 
treatment published worldwide are relatively 
scarce, but still very indicative. They all point 
out the high costs resulting from the treat-
ment of this disease, as well as significant 
differences between costs for inpatients and 
outpatients treatment. According to Guest 
and Morris’ report, published in 1997 [8], the 
British National Health Service (NHS) spent 
£ 1,364.3 million for treatment of 16.3 mil-
lion episodes of community-acquired lower 
respiratory tract infections, out of which 32% 
(£ 440.7 million) were spent for CAP treat-
ment. This amount (£ 440.7 million) was 
spent treating 261,000 annual episodes of 
CAP; 32% of these epidoses were inpatient 
stays, which accounted for 96% of the total 
direct costs of CAP and 87% of total annual 
costs. Costs for outpatients (corresponding to 
68% of total CAP cases) accounted for only 
4% of total annual costs. This analysis shows 
that the average cost of managing pneumonia 
in the UK community is £ 100 per episode, 
while the cost of inpatient treatment var-
ies from £1.700 to £ 5,100 per episode, de-
pending on the length of hospitalization and 
complications. All estimated costs were cal-
culated according to prices from 1992/1993. 
According to prices from 1995/1996, the 
costs have already been uprated from £ 440.7 
to £ 480.4 million.
In 1998 Niederman and colleagues [14] pub-
lished a retrospective study, which showed 
that an average cost of CAP treatment in in-
patients in the USA is US$ 7166, for patients 
aged ≥ 65, with an average length of stay of 
7.8 days. For patients aged less than 65, aver-
age cost of treatment is US$6042, and aver-
age lenth of stay is 5.8 days. The Authors cal-
culated a total cost of US$ 8.4 billion (US$ 
4.8 billion for treatment of CAP patients aged 
≥ 65, US$ 3.6 billion for treatment of patients 
aged less then 65). Respectivelly, 95% (for 
patients aged ≥ 65) and 81% (for patients 
aged < 65) of all CAP treatment costs are 
generated from inpatient treatment.
Orrick and colleagues [15] reported results 
from their pharmacoeconomic study in 2004, 
with 99 CAP inpatients enrolled, treated 
in USA hospitals. According to the results, 
mean cost of hospitalization per admis-
sion was US$ 3,490 ± 3058, with hospital 
room/board accounting for largest percent-
age (83.7%), followed by laboratory (8.1%), 
antibacterial (4.6%), radiology (2.6%) and 
respiratory support cost (0.9%). The group 
treated according to current guidelines of 
the Infectious Diseases Society of America 
(1998) had a shorter mean length of hospi-
tal stay (4.5 days) and a lower total cost of 
hospitalization (US$3009 ± 2682), and lower 
antibacterial costs (US$117 ± 79), compared 
to group of patients which were not treated 
according to the guidelines (mean length of 
hospitalization was 6.8 days, mean hospital-
ization costs US$4992 ± 3686, antibacterial 
therapy US$301 ± 409).
Bartolome and colleagues [9] reported results 
from population-based study which was con-
ducted in Spain in 2004. According to these 
results, the mean direct cost of CAP treat-
ment in the hospital setting was €1553 ± 542, 
and the cost structure was dominated by hos-
pitalization, which accounts for 84.4% of all 
costs. The cost of treating the same disease 
for outpatients was €196 ± 86. Further analy-
sis of the obtained results and possible cost 
reductions pointed out that 15.7% of hospital 
admissions were estimated as inadequate/un-
necessary, and that these patients could have 
been treated completely as outpatients, while 
the mean length of stay (10.8±6.2 days) could 
have been reduced by 3.5 days, in the most 
severe cases. The reduction of number of in-
adequate hospitalizations and length of stay 
in hospital would lead to overall cost reduc-
tion of 17.4%. In conclusion of their analysis, 
the Authors stated that 22% of patients could 
have been discharged from the hospital set-
ting during the first 3 days from admission, 
and short hospitalizations followed by exten-
sion of treatment on other health care sys-
tem levels (primary health care, ambulatory, 
home care) should be strongly encouraged.
In the same year (2004), Colice and col-
leagues [10] published a survey in which 
they calculated the rate of hospitalization in 
a sample of 7249 episodes of community-
acquired pneumonia recorded in 6415 em-
ployed patients. The calculated hospitaliza-
tion rate was 19.6%, and the mortality rate 
in hospitalized patients was 9.1%. The mean 
value of CAP episode treatment cost (includ-
ing the inpatient and eventual previous am-
bulatory treatment costs) was US$ 10,227 ± 
15,342, while the mean value of treatmant for 
outpatients was US$ 466 ± 1038. These costs 
were significantly higer than the previous es-
timates. Total annual cost of CAP treatment 
in the USA is estimated to 12.2 billion US$.
Bauer and colleagues [16] analyzed costs re-
lated to CAP from the hospital perspective. 
The results of their study were published in 
2005 and comprised data from 22 hospitals in 
Germany, with 580 patients treated with stan-
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dard (fluoroquinolones) and non-standard 
(beta-lactams and macrolides) therapy. Mean 
length of stay in hospital was 10.8 ± 5.2 days 
(10.0 ± 4 days in patients treated with stan-
dard therapy and 11.5 ± 6 days in those treat-
ed with non-standard therapy). Mean value of 
all direct expenses was US$ 1,250 (in the first 
group) and US$ 1,409 (in the second group), 
for each CAP episode treatment. In 1997, di-
rect and indirect costs of CAP treatment in 
Germany were estimated to be equal to 1.64 
billion US$, out of which 983 million US$ 
were direct costs and 656 million US$ were 
indirect costs (e.g., costs related to employ-
ers’ losses). Outpatient treatment costs (US$ 
32.8 million for medicaments and US$ 45.9 
million for other treatment costs) were rela-
tively low, while the costs incurred due to the 
inpatient treatment were estimated at 896 
million US$ (90% of direct expenses) and 
they represent significant burden on health 
care system and insurance.
Reyes and colleagues [11] published a sur-
vey in 2008 in which they analyzed cost 
determinants for inpatient CAP treatment in 
Spain. The study involved 271 patients, hos-
pitalized due to community-acquired pneu-
monia. According to available data and cal-
culations, mean value of treatment costs per 
patient was € 1,683 (€ 1,291-2,471), while 
the costs of hospital stay dominated in the 
total cost structure (€ 1,286 (€ 857-1,714)), 
followed by the costs of laboratory analyses 
(€ 212 (€ 171-272)), therapy (€ 187 (€ 114-
304)) and diagnostic procedures (€ 58 (€ 29-
122)). Complications occurence and higher 
PSI (Pneumonia Severity Index) score were 
related to increased costs, while the age and 
comorbidities were not. In conclusion, com-
plications – especially hypoalbuminemia and 
previous hospitalization – were main deter-
minants of high direct costs of CAP hospi-
talization.
Available data indicate that the percentage of 
CAP patients treated in hospital setting varies 
from 18 to 60% [9]. Numerous and various 
factors have influence on this, such as: age, 
comorbidities, hospital availability, social 
reasons, lack of trust in patient’s compliance, 
and other subjective criteria with crucial 
impact in the moment of decision making 
whether the patient will be hospitalized or 
not. Clinicians tend to hospital admission 
whenever there is doubt about positive out-
come of outpatient treatment [17].
The results of the study also indicate that 
shorter course hospitalizations did not in-
crease mortality rate after hospital discharge 
or hospital re-admission rate, but there is no 
unique opinion regarding the optimal length 
of stay in hospital for CAP patients [18]. Av-
erage duration of antibiotic therapy in out-
patients should be 8 to 10 days, for low risk 
CAP patients [19], but most frequent litera-
ture data suggest 14-days antibiotic treatment 
[9]. According to some studies, intravenous 
antibiotic treatment lasted 6 to 7 days [9,20]. 
However, intravenuous antibiotic treatment 
of 2 to 3 days could be equally effective and 
could lead to reduced length of stay in hospi-
tal and reduced expenses in low risk patients 
[20]. According to data from the literature, 
time period from clinical resolution to return 
to normal working activities was even up to 
22 to 25 days [9,21], which is attributed to 
persistance of some symptoms such as fa-
tigue, patient’s age but also waiting time until 
complete radiographic resolution.
In total cost structure, therapy comprises 
10 to 15% of total CAP treatment costs 
[9-11,16,18]. According to Reyes and col-
leagues [11], 79% corresponds to antibiotic 
therapy costs, whereas this percentage var-
ies depending on the type of antibiotic used, 
severity of disease and estimated complica-
tions that could occur. Bauer and colleagues 
[16] suggested that the use of more expensive 
antibiotics such as fluoroquinolones may be 
associated with shorter length of hospitaliza-
tion and does not induce changes in the total 
expenditure.
It is interesting to compare the differences in 
the costs of inpatient and outpatient (ambula-
tory) treatment of community-acquired pneu-
monia. Bartolome and colleagues [9] indicate 
that the expenses of inpatient CAP treatment 
are 7.9 times higher than those of outpatient 
treatment, and in case of complications and 
extended hospitalization, this difference can 
be even 17 to 51 times higher [8,22,23].
Total costs of CAP treatment in the USA (in-
cluding indirect ones) are estimated to reach 
US$ 12.2 billion, out of which US$ 10.3 bil-
lion count for treatment in the hospital set-
ting (one million of hospitalizations x US$ 
10,233, which represents the average cost per 
patient), and US$ 1.9 billion count for the 
cost of outpatient treatment (4.1 million cas-
es x US$ 466, which is the average cost per 
ambulatory treated patient with CAP) [10].
The variability of direct costs is mostly in-
fluenced by the length of hospitalization. The 
authors agree that the significant number of 
CAP episodes can be treated ambulatory, and 
the great number of hospitalizations could be 
avoided in that way [9], which could lead to 
reduction of costs attributed to hospitaliza-
tion and hospital stay. Strict guidelines com-
pliance would be a significant step in cost 
reduction, primarily in terms of Pneumonia 
Severity Index, which enables the stratifica-
tion of patients in risk categories at the admis-
137Farmeconomia. Health economics and therapeutic pathways 2012; 13(3) © SEEd All rights reserved
V. Cupurdija, Z. Lazic, M. Jakovljevic
sion and facilitates decision making process 
regarding the place of treatment and therapy 
which is to be initiated. Results of recent 
studies indicate that it is possible to shorten 
the length of hospital treatment without jeop-
ardizing patient’s health or influencing the 
outcome of the disease. Capelastegui and col-
leagues indicate that the average length of in-
patient treatment was reduced from 5.6 days 
in 2000 and 2001 to 3.7 days in 2006 and 
2007 [24]. The important data is that 22% of 
patients could be discharged to home treat-
ment (outpatients) during the first three days 
from the admission and short hospitalizations 
followed by further treatment and extended 
care at other health care levels should be seri-
ously concerned (primary health care, home 
care) [9]. The most significant costs are made 
during the first 2 or 3 days of inpatient treat-
ment, and afterwards they are followed by 
cost decrease [18].
Table I summarizes the results of the main 
studies on CAP cost of illnesss.
COMMUNITY-ACQUIRED 
PNEUMONIA: FUTURE COST 
CONTAINMENT STRATEGIES
There is a certain peculiarity of Serbian 
health care setting with regards to respira-
tory diseases. Serbia is a small post-socialist 
transitional market with heavy burden of 
centrally planned economy in the past. Even 
today it reflects to the patterns of health care 
Type of illness Country Study type Results Costs Author/year [ref]
Community-
acquired lower 
respiratory tract 
infections
UK Prevalence based 
burden-of-illness 
analysis
Total direct outpatient/
inpatient medical costs 
per episode
£ 100/£ 1,700-5,100 Guest et al, 1997 [8]
CAP USA Retrospective 
costs- to-the 
Health care 
system analysis
Average cost of 
treatment in inpatients 
for patients aged 
≥ 65/< 65
US$ 7166/$ 6042 Niederman et al, 1998 [14]
CAP USA Multicentre 
observational 
study
Mean cost of 
hospitalization per 
admission
US$ 3,490 ± 3,058 Orrick et al, 2004 [15]
CAP Spain Prospective cost 
analysis study
Mean direct inpatient/ 
outpatient cost of 
treatment
€ 1,553 ± 542/€ 196 
± 86
Bartolome et al, 2004 [9]
CAP USA Retrospective 
cost-of-illness 
study
Mean direct inpatient/ 
outpatient cost of 
treatment
US$ 10,227 ± 
15,342/US$ 466 ± 
1,038
Colice et al, 2004 [10]
CAP Germany Retrospective cost 
analysis study
Mean direct inpatient 
cost of treatment with 
standard/non-standard 
therapy
US$ 1,250/US$ 1,409 Bauer et al, 2005 [16]
CAP Spain Prospective 
observational cost 
analysis study
Mean direct inpatient 
cost of treatment
€ 1,683 (€ 1,291-
2,471)
Reyes et al, 2004 [11]
Table I. Main cost-of-illness trials on CAP
funding and management [25]. It should not 
be forgotten that tobacco addiction is widely 
spread in this Country, with rates that are 
much higher than OECD average, and this of 
course affects CAP incidence [26]. Besides, 
it is one of seldom European societes report-
ing increase in pulmonary carcinoma inci-
dence [27]. Official statistics for CAP inci-
dence and mortality in Serbia are missing, so 
we can base our estimations on scarce CAP 
incidence data reported for Mediterranean 
countries with similar prevailing lifestyle 
and underlying behavioral risks (Italy, Spain) 
[5,6]. Serbian budget allocation for health 
care funding out of gross domestic product 
available is estimated equal to 9.9% and 
some US$ 419 per person per year, according 
to available and official WHO statistics for 
2009 [7]. Findings of the few local cost of ill-
ness estimates among major diseases (type 2 
diabetes mellitus, addiction disorders, cancer, 
risky pregnancies) [28-31], imply that out-of-
pocket citizen’s expenditure for medical care 
heavily overweights governmental subven-
tions. CAP is no exception. Based on the ex-
periences from high income economies, we 
estimate that CAP budget impact in Serbia 
will grow further in coming years. Reasons 
for this trend are both the rasing health care 
expenditure and the higher affordability of 
services which are likely to affect consumer 
demand for quality medical care among ordi-
nary citizens [25].
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There are several strategies which can possi-
bly contain outpatient pneumonia costs. First 
of all, it is necessary to highlight the impor-
tance of vaccination, especially in the vulner-
able population, implementing prophylaxis 
and pneumococcal and flu vaccination pro-
grams [8]. Furthermore, it is important to 
develop strategies to prevent and minimize 
hospitalization, by adhering the clinical ad-
mission guidelines [8] (reducing the number 
of inpatients and reducing the lengh of hospi-
tal stay), with more effective out of hospital 
management. The early justified application 
of antibiotic therapy and the early transfer 
from intravenous to oral therapy, as well as 
prevention of complications during the hos-
pitalization are very important [11].
It is certain that such interventions could jus-
tify themselves in the Serbian national health 
sector. Here outsourcing net savings would 
contribute substantially to resolve ongoing 
health care funding difficulties [25]. Pub-
lished data on similar studies conducted in 
the Balkans examining CAP treatment cost 
within local clinical setting are missing. Also, 
there are no data on the degree of initially as-
sessed illness severity, length of hospitaliza-
tion and the occurence of complications that 
prolong the hospitalization, increasing the 
treatment costs and disease mortality rate. 
Due to the current working environment in 
health care institutions, in conditions of per-
manent restriction imposed by the Republic 
Health Insurance Fund, rational use of health 
resources has an increasing importance. The 
long-term problem of health care sector man-
agement remains how to provide optimal 
quantity and quality of population health care 
by means of limited funds and resources.
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